prof. Filip Van den Bosch
work address
De Pintelaan 185, 0K12-IB
9000 Gent
9000 Gent
ORCID iD
0000-0002-3561-59321 – 10 of 106
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
- Immunoscintigraphic detection of tumour necrosis factor by radiolabelled certolizumab pegol in patients with erosive hand osteoarthritis : a proof-of-concept study
- ASAS definition for sacroiliitis on MRI in SpA : applicable to children?
- 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
- Whipple’s disease in granulomatous disguise: a challenging diagnosis with many histopathological pitfalls
- Efficacy and safety of non-pharmacological and non-biological pharmacological treatment : a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis
- Efficacy and safety of biological and targeted-synthetic DMARDs : a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis
- The performance of different classification criteria sets for spondyloarthritis in the worldwide ASAS-COMOSPA study
- An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease : a case series
- Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study
- Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis : results from a randomised phase III trial (FUTURE 1)